glaucoma
Conditions
Interventions
Observation group:None
Sponsors
West China Hospital of Sichuan University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Age > 18 years, any gender; 2. All subjects must have BCVA >= 0.1 and intraocular pressure between 21 and 40 mmHg; 3. Clearly diagnosed by a glaucoma specialist with primary open-angle glaucoma (POAG), ocular hypertension, or normal-tension glaucoma (NTG), but have not yet used any anti-glaucoma treatments, including intraocular pressure-lowering eye drops or surgery; 4. Subjects must be able to communicate effectively with the researchers, understand the key contents of the informed consent form, and provide informed consent before undergoing any study-specific assessments or procedures in order to participate in the study (if the subject is legally blind or illiterate, a notary must be present throughout the informed consent discussion).
Exclusion criteria
Exclusion criteria: 1. Subjects who have previously undergone antiglaucoma surgery, used intraocular pressure-lowering eye drops (except those after a 1-year washout period), received ophthalmic incisional surgery within the past 3 months, or underwent laser treatment in the previous month. Subjects who have experienced an acute glaucoma episode (such as acute angle-closure glaucoma or glaucoma crisis); 2. Subjects whose intraocular pressure is poorly controlled or whose visual field MD progresses too rapidly after using intraocular pressure-lowering medications, requiring further surgical treatment, will be withdrawn from the study; 3. Subjects with clinically significant cataracts affecting imaging or visual field examinations, or those with a history of cataract surgery; 4. Subjects with any active infection or inflammation in the anterior or posterior segment of the eye, as well as patients diagnosed with moderate to severe dry eye; 5. Subjects with diabetic retinopathy, diabetic macular edema, or other vitreoretinal disorders; 6. Subjects with a history of keratoconus or other corneal diseases, including infectious and hereditary conditions, corneal scars, and degeneration; 7. Subjects with a history of ocular trauma or refractive surgery, such as laser in situ keratomileusis (LASIK); 8. Subjects with systemic diseases that may affect visual function or fundus morphology, such as diabetes, leukemia, AIDS, and uncontrolled hypertension; 9. Subjects with systemic diseases that may cause corneal lesions, such as connective tissue disorders, arthritis, or hereditary metabolic disorders; 10. Female subjects who are pregnant or breastfeeding; 11. Subjects unable to maintain good fixation, or those with poor compliance for various reasons, making them unable to cooperate with the trial; 12. Subjects deemed unsuitable by the investigator to participate in this clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| corneal nerve fiber density;corneal nerve branch density;corneal nerve fiber length; | — |
Countries
China
Contacts
Public ContactNi Li
West China Hospital of Sichuan University
Outcome results
None listed